KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
发明人:
PARK, YOUNG WOO,박영우,JO, KI WON,조기원,CHO, KYU WON,조규원,PARK, JI HYUN,박지현,HYUN, SOON SIL,현순실,PARK, YUN JUNG,박윤정
申请号：
KR1020110018628
公开号：
KR1020120100027A
申请日:
2011.03.02
申请国别(地区):
KR
年份:
2012
代理人:
摘要：
PURPOSE: A pharmaceutical composition for cancer prevention or treatment including endocytic motif and protein introduction domain is provided to specifically inhibit endocytosis of c-Met by polypeptide in order to effectively inhibits HGF/c-Met signal transmission path and inhibit transition, infiltration, vascularization and growth of cancer.CONSTITUTION: A pharmaceutical composition for cancer prevention or treatment includes endocytic motif which is represented as amino acid sequence having the sequence number 1(SEQ ID NO:1). The motif is imported inside cells by clathrin mediated endocytosis. The motif is c-Met, phosphorylated c-Met, or c-Met combined with HGF(hepatocyte growth factor). The motif inhibits self - phosphorylation of c-Met by HGF. The Pharmaceutical composition for preventing or treating cancers includes motif as an active ingredient. A fused polypeptide is endocytotic motif-C terminal represented by equation 1: N-terminal-protein transduction domain-amino acid sequence having the sequence number 1 or endocytic motif - protein transduction domain -C terminal represented by equation 2: N- terminal-amino acid sequence having the sequence number 1. The protein transduction domain is Tat of HIV(human immunodeficiency virus) VP22 of HSP(herpes simplex virus) Antp of pomace fly Mph-1 Sim-2 R7 Pep-1 or Pep-2.COPYRIGHT KIPO 2013본 발명은 서열번호 1의 아미노산 서열로 표시되는 엔도사이토시스 모티프(endocytic motif), 상기 모티프 및 단백질 도입 도메인을 포함하는 융합 폴리펩티드 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명은 c-Met의 엔도사이토시스를 특이적으로 억제하여 다양한 암 세포의 전이 및 성장과 관련된 HGF/c-Met 신호전달 경로를 효과적으로 억제함으로써 암의 전이, 침윤, 혈관신생 및 성장을 억제할 수 있는 효과를 가지고 있다. 따라서, 본 발명은 다양한 암에 대한 항암제로서 유용하게 사용할 수 있다.
